Innoviva Management

Management criteria checks 2/4

Innoviva's CEO is Pavel Raifeld, appointed in May 2020, has a tenure of 3.92 years. total yearly compensation is $1.80M, comprised of 24.5% salary and 75.5% bonuses, including company stock and options. directly owns 0.018% of the company’s shares, worth €166.41K. The average tenure of the management team and the board of directors is 3.9 years and 6.2 years respectively.

Key information

Pavel Raifeld

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage	24.5%
CEO tenure	3.9yrs
CEO ownership	0.02%
Management average tenure	3.9yrs
Board average tenure	6.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Pavel Raifeld's remuneration changed compared to Innoviva's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	US$180m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$233m
Mar 31 2023	n/a	n/a	US$233m
Dec 31 2022	US$2m	US$440k	US$214m
Sep 30 2022	n/a	n/a	US$293m
Jun 30 2022	n/a	n/a	US$99m
Mar 31 2022	n/a	n/a	US$188m
Dec 31 2021	US$1m	US$391k	US$266m
Sep 30 2021	n/a	n/a	US$309m
Jun 30 2021	n/a	n/a	US$265m
Mar 31 2021	n/a	n/a	US$253m
Dec 31 2020	US$2m	US$222k	US$224m

Compensation vs Market: Pavel's total compensation ($USD1.80M) is above average for companies of similar size in the German market ($USD1.29M).

Compensation vs Earnings: Pavel's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Pavel Raifeld (39 yo)

3.9yrs

Tenure

US$1,798,966

Compensation

Mr. Pavel Raifeld, CFA, is Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive wi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Pavel Raifeld	Chief Executive Officer	3.9yrs	US$1.80m	0.018% $ 166.4k
Marianne Zhen	Chief Accounting Officer & Secretary	5.8yrs	US$771.13k	0.075% $ 678.5k
Stephen Basso	Chief Financial Officer	less than a year	no data	no data

3.9yrs

Average Tenure

54yo

Average Age

Experienced Management: HVE's management team is considered experienced (3.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jules Haimovitz	Independent Director	6.2yrs	US$523.54k	0.16% $ 1.4m
Sapna Srivastava	Independent Director	1.3yrs	no data	0% $ 0
Odysseas Kostas	Independent Director	6.3yrs	US$407.49k	0.15% $ 1.3m
Sarah Schlesinger	Independent Director	6.2yrs	US$435.12k	0.14% $ 1.3m
Mark DiPaolo	Independent Director	6.2yrs	US$407.49k	0.14% $ 1.3m

6.2yrs

Average Tenure

52yo

Average Age

Experienced Board: HVE's board of directors are considered experienced (6.2 years average tenure).

Innoviva Management

Management criteria checks 2/4

Key information

Recent management updates

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Independent Chairman of the Board recently bought €216k worth of stock

Recent updates

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

First quarter 2023 earnings released: EPS: US$0.51 (vs US$0.23 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings released: EPS: US$3.81 (vs US$1.04 in 3Q 2021)

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Second quarter 2022 earnings released: EPS: US$0.013 (vs US$1.01 in 2Q 2021)

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Independent Chairman of the Board recently bought €216k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

New 90-day high: €10.20

New 90-day high: €10.00

Investor sentiment improved over the past week

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Third quarter earnings released

New 90-day low: €8.40

New 90-day low: €9.25

New 90-day low - €10.60

New 90-day low - €11.10

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age